Literature DB >> 34506672

Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes.

Petr Szturz1, Jan B Vermorken2,3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34506672      PMCID： PMC8571739          DOI： 10.1002/onco.13966

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  14 in total

1.  Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

Authors:  Kartik Sehgal
Journal:  JAMA Netw Open       Date:  2021-03-01

2.  Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; H E Gall; C J van Groeningen; G A Hart; H M Pinedo
Journal:  Clin Pharmacol Ther       Date:  1986-02       Impact factor: 6.875

3.  Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

Authors:  Joël Guigay; Anne Aupérin; Jérôme Fayette; Esma Saada-Bouzid; Cédrik Lafond; Miren Taberna; Lionnel Geoffrois; Laurent Martin; Olivier Capitain; Didier Cupissol; Hélène Castanie; Damien Vansteene; Philippe Schafhausen; Alison Johnson; Caroline Even; Christian Sire; Sophie Duplomb; Camille Evrard; Jean-Pierre Delord; Brigitte Laguerre; Sylvie Zanetta; Cécile Chevassus-Clément; Aldéric Fraslin; Fanny Louat; Laura Sinigaglia; Ulrich Keilholz; Jean Bourhis; Ricard Mesia
Journal:  Lancet Oncol       Date:  2021-03-05       Impact factor: 41.316

Review 4.  Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.

Authors:  Myung-Ju Ahn; Anil D'Cruz; Jan B Vermorken; Jo-Pai Chen; Imjai Chitapanarux; Huy Quoc Thinh Dang; Alex Guminski; Danita Kannarunimit; Tong-Yu Lin; Wai Tong Ng; Keon-Uk Park; Anthony Tak Cheung Chan
Journal:  Oral Oncol       Date:  2015-12-19       Impact factor: 5.337

5.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Authors:  Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin
Journal:  Lancet       Date:  2019-11-01       Impact factor: 79.321

6.  Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.

Authors:  Filipa Pontes; Ana Rita Garcia; Isabel Domingues; M João Sousa; Rita Felix; Cláudia Amorim; Fábio Salgueiro; Mónica Mariano; Margarida Teixeira
Journal:  Cancer Treat Res Commun       Date:  2021-04-14

7.  Translating KEYNOTE-048 into practice recommendations for head and neck cancer.

Authors:  Petr Szturz; Jan B Vermorken
Journal:  Ann Transl Med       Date:  2020-08

Review 8.  Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer.

Authors:  Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; David Adelstein; Dirk Van Gestel; Jan B Vermorken
Journal:  Front Oncol       Date:  2019-02-21       Impact factor: 6.244

Review 9.  Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes.

Authors:  Samuel I Kim; Christopher R Cassella; Katelyn T Byrne
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.